Cargando…

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control

INTRODUCTION: Daily dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used with other orally administered antihyperglycemic agents (AHA), as combination therapy, to treat Japanese patients with type 2 diabetes. When combination therapy is indicated, use of a once-weekly (q.w.) orally administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Gantz, Ira, Okamoto, Taro, Ito, Yuka, Sato, Asako, Okuyama, Kotoba, O’Neill, Edward A., Engel, Samuel S., Lai, Eseng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544607/
https://www.ncbi.nlm.nih.gov/pubmed/28589493
http://dx.doi.org/10.1007/s13300-017-0270-7
_version_ 1783255272120123392
author Gantz, Ira
Okamoto, Taro
Ito, Yuka
Sato, Asako
Okuyama, Kotoba
O’Neill, Edward A.
Engel, Samuel S.
Lai, Eseng
author_facet Gantz, Ira
Okamoto, Taro
Ito, Yuka
Sato, Asako
Okuyama, Kotoba
O’Neill, Edward A.
Engel, Samuel S.
Lai, Eseng
author_sort Gantz, Ira
collection PubMed
description INTRODUCTION: Daily dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used with other orally administered antihyperglycemic agents (AHA), as combination therapy, to treat Japanese patients with type 2 diabetes. When combination therapy is indicated, use of a once-weekly (q.w.) orally administered DPP-4 inhibitor might be an appropriate therapeutic option for some patients. METHODS: A 52-week trial was conducted to assess the safety and tolerability (primary objectives) and glycemic efficacy (secondary objectives) of the q.w. DPP-4 inhibitor omarigliptin as add-on therapy to five different classes of orally administered AHA [sulfonylurea (SU), glinide (GL), biguanide (BG), thiazolidinedione (TZD), or α-glucosidase inhibitor (AGI)] commonly used in Japan and having different mechanisms of drug action from DPP-4 inhibitors. The trial consisted of an initial 24-week double-blind, placebo-controlled period during which patients (stratified by background AHA) were randomized to omarigliptin 25 mg q.w. or placebo, followed by a 28-week open-label period during which patients on placebo were switched to omarigliptin. RESULTS: After 24 weeks, the percentages of patients with adverse events (AEs), serious AEs, drug-related AEs, AEs of symptomatic hypoglycemia, or who discontinued from trial medication because of an AE were generally similar in the omarigliptin and placebo groups, in all background AHA strata and in the overall population. From a mean baseline HbA1c of approximately 8.0%, the placebo-adjusted least-squares mean changes from baseline ranged from −0.80% (AGI stratum) to −1.16% (TZD stratum); p < 0.001 for all background AHA strata. During the open-label period, no safety signals emerged with longer-term treatment. At week 52, the change from baseline in HbA1c in the omarigliptin/omarigliptin group was similar to that of the placebo/omarigliptin group. CONCLUSIONS: Addition of once-weekly omarigliptin to AHA therapy with an SU, GL, BG, TZD, or AGI for up to 52 weeks was generally safe and well tolerated, and provided persistent efficacy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT01697592. FUNDING: MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-017-0270-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5544607
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-55446072017-08-18 A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control Gantz, Ira Okamoto, Taro Ito, Yuka Sato, Asako Okuyama, Kotoba O’Neill, Edward A. Engel, Samuel S. Lai, Eseng Diabetes Ther Original Research INTRODUCTION: Daily dipeptidyl peptidase-4 (DPP-4) inhibitors are commonly used with other orally administered antihyperglycemic agents (AHA), as combination therapy, to treat Japanese patients with type 2 diabetes. When combination therapy is indicated, use of a once-weekly (q.w.) orally administered DPP-4 inhibitor might be an appropriate therapeutic option for some patients. METHODS: A 52-week trial was conducted to assess the safety and tolerability (primary objectives) and glycemic efficacy (secondary objectives) of the q.w. DPP-4 inhibitor omarigliptin as add-on therapy to five different classes of orally administered AHA [sulfonylurea (SU), glinide (GL), biguanide (BG), thiazolidinedione (TZD), or α-glucosidase inhibitor (AGI)] commonly used in Japan and having different mechanisms of drug action from DPP-4 inhibitors. The trial consisted of an initial 24-week double-blind, placebo-controlled period during which patients (stratified by background AHA) were randomized to omarigliptin 25 mg q.w. or placebo, followed by a 28-week open-label period during which patients on placebo were switched to omarigliptin. RESULTS: After 24 weeks, the percentages of patients with adverse events (AEs), serious AEs, drug-related AEs, AEs of symptomatic hypoglycemia, or who discontinued from trial medication because of an AE were generally similar in the omarigliptin and placebo groups, in all background AHA strata and in the overall population. From a mean baseline HbA1c of approximately 8.0%, the placebo-adjusted least-squares mean changes from baseline ranged from −0.80% (AGI stratum) to −1.16% (TZD stratum); p < 0.001 for all background AHA strata. During the open-label period, no safety signals emerged with longer-term treatment. At week 52, the change from baseline in HbA1c in the omarigliptin/omarigliptin group was similar to that of the placebo/omarigliptin group. CONCLUSIONS: Addition of once-weekly omarigliptin to AHA therapy with an SU, GL, BG, TZD, or AGI for up to 52 weeks was generally safe and well tolerated, and provided persistent efficacy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT01697592. FUNDING: MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13300-017-0270-7) contains supplementary material, which is available to authorized users. Springer Healthcare 2017-06-06 2017-08 /pmc/articles/PMC5544607/ /pubmed/28589493 http://dx.doi.org/10.1007/s13300-017-0270-7 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Gantz, Ira
Okamoto, Taro
Ito, Yuka
Sato, Asako
Okuyama, Kotoba
O’Neill, Edward A.
Engel, Samuel S.
Lai, Eseng
A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
title A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
title_full A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
title_fullStr A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
title_full_unstemmed A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
title_short A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
title_sort randomized, placebo-controlled trial evaluating the safety and efficacy of adding omarigliptin to antihyperglycemic therapies in japanese patients with type 2 diabetes and inadequate glycemic control
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544607/
https://www.ncbi.nlm.nih.gov/pubmed/28589493
http://dx.doi.org/10.1007/s13300-017-0270-7
work_keys_str_mv AT gantzira arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT okamototaro arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT itoyuka arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT satoasako arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT okuyamakotoba arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT oneilledwarda arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT engelsamuels arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT laieseng arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT arandomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT gantzira randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT okamototaro randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT itoyuka randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT satoasako randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT okuyamakotoba randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT oneilledwarda randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT engelsamuels randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT laieseng randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol
AT randomizedplacebocontrolledtrialevaluatingthesafetyandefficacyofaddingomarigliptintoantihyperglycemictherapiesinjapanesepatientswithtype2diabetesandinadequateglycemiccontrol